Abstract
Approximately 15% to 25% or 75,000 ischemic strokes are attributed to atrial fibrillation annually within the United States. Atrial fibrillation is the most frequently diagnosed cardiac arrhythmia and affects more than 2.66 million Americans. Moreover, atrial fibrillation is associated with a 1.5 to 1.9-fold higher risk of death due to its strong correlation with thromboembolic events. Because of the attributed increased morbidity and mortality, challenges that concern identification of patients at risk for thromboembolic events from atrial fibrillation must be addressed. These challenges include compliance to performance measures, adherence to guidelines, adequate prevention and early control of co-morbidities that affect the progression of atrial fibrillation and associated risks, early initiation of treatment, and successful evaluation of associated risks of bleeding, primary or recurrent stroke, and patient awareness and compliance.
This multimedia educational webcast will discuss the state of affairs with respect to antithrombotic therapies and new anticoagulants. The webcast will also review factors influencing physician use of anticoagulation in atrial fibrillation. Clinical decision making and lessons learned from the expert faculty is also included.
Online Access: http://elseviercme.com/ajc/cv1 .
This CME Multimedia Activity is also available through the Web site of The American Journal of Cardiology ( www.ajconline.org/ ). Click on the CME Multimedia Activity button in the navigation bar for full access.
Author Disclosures
It is the policy of the Elsevier Office of Continuing Medical Education (EOCME) that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Chris Cannon, MD, FACC , is a consultant/advisor for Alnylam Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Pfizer Inc., and CSL Behring; has received a research grant from Accumetrics , AstraZeneca , Essentialis, Inc. , GlaxoSmithKline , Merck & Co., Inc. , Regeneron Pharmaceuticals, Inc. , sanofi-aventis , Takeda Pharmaceutical Company Limited ; and has stock ownership in Automedics Medical Systems, Inc.
Michael D. Ezekowitz, MBChB, DPhil, FACC , is a consultant/advisor for Aegerion Pharmaceuticals, Inc., Bayer Healthcare, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Coherex Medical, Inc., Daiichi Sankyo, Inc., Gilead Sciences, Inc., Janssen Scientific Affairs, LLC, Johnson & Johnson, Inc., Medtronics, Inc., Merck & Co., Inc., Pfizer Inc., Portola Pharmaceuticals, Inc, Pozen, Inc., sanofi-aventis; and has received grant/research support from Boehringer Ingelheim Pharmaceuticals, Inc. , Daiichi Sankyo, Inc. , and Portola Pharmaceuticals, Inc .
Christopher Granger, MD, FACC , is a consultant/advisor for AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline, Hoffman La-Roche, Ltd., Pfizer Inc., sanofi-aventis, Takeda Pharmaceutical Company Limited, The Medicines Company; has received grant/research support from Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb Company , GlaxoSmithKline, Medtronic Foundation , Merck & Co., Inc., Pfizer Inc. , sanofi-aventis, Takeda Pharmaceutical Company Limited, and The Medicines Company .
Planners, Managers, Reviewers: Timothy Hayes, MD, PhD, Karen Overstreet, EdD, RPh, FACEHP, CCMEP, Margaret Taylor, Gena Dolson, MS, Esther Polgar, Sandy Breslow, and Jill McNair hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.
Acknowledgment
This multimedia activity was peer reviewed by The American Journal of Cardiology and is cosponsored by the Elsevier Office of Continuing Medical Education and AcademicCME .
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
